中国药业2016，Vol.25Issue(19)：13-16,4.
前列地尔联合α－硫辛酸及甲钴胺治疗初诊2型糖尿病周围神经病变疗效观察
Prostaglandin E1 Combined with Alpha Lipoic Acid and Mecobalamin in Treating First Diagnosis of Type 2 Diabetes Peripheral Neuropathy
摘要
Abstract
Objective To observe the clinical efficacy of prostaglandin E1, alpha lipoic acid and mecobalamin on first diagnosis of type 2 diabetes peripheral neuropathy. Methods 350 patients with first diagnosis of type 2 diabetes peripheral neuropathy were selected and randomly divided into the prostaglandin E1+alpha lipoic acid+mecobalamin group 71 cases;prostaglandin E1+alpha lipoic acid group 69 cases; alpha lipoic acid+mecobalamin group 72 cases; prostaglandin E1+mecobalamin group 68 cases; control group 70 cases. The nerve conduction velocity , sensory symptoms and overall clinical efficacy were compared before and after treatment among the 5 groups. Results The nerve conduction velocity and the clinical symptoms of feeling in the 4 treatment groups improved compared with before treatment ( P < 0. 01 ); compared with the control group, the 4 treatment groups improved significantly better, the difference between groups was statistically significant ( P < 0. 01 ) , and the prostaglandin E1+alpha lipoic acid+mecobalamin group improved the most significantly. Conclusion On the basis of blood sugar control, comprehensive therapy of prostaglandin E1, alpha lipoic acid and mecobalamin is the key in treating and improving diabetic peripheral neuropathy.关键词
初诊2型糖尿病周围神经病变/前列地尔/α-硫辛酸/甲钴胺Key words
first diagnosis of type 2 diabetes peripheral neuropathy/Prostaglandin E1/alpha lipoic acid/mecobalamin分类
医药卫生引用本文复制引用
杨昕,刘志民..前列地尔联合α－硫辛酸及甲钴胺治疗初诊2型糖尿病周围神经病变疗效观察[J].中国药业,2016,25(19):13-16,4.基金项目
国家自然科学基金，项目编号30872416；上海市科委课题，项目编号04DZ19503。 （）
